About Stem Cell UCB
UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. UCB contains stem cells that are unique, smart, and are capable of treating several life-threatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce 10 times more quantity of stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood that is collected during the childbirth is stored and cryopreserved. The storage of the cord blood can be done at private cord blood banks or public cord blood banks. This preserved blood can be used for the transplantation, and treatment of diseases at the later stages of life.
Technavio's analysts forecast the global stem cell UCB market to grow at a CAGR of 30.36% over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global stem cell UCB market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the banking and utilization of UCB stem cells for the treatment of various disorders, such as cancers, blood disorders, metabolic disorders, immune diseases, and others.
Technavio's report, Global Stem Cell UCB Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global stem cell UCB market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Caladrius Biosciences
• Celgene
• Mesoblast
• Pluristem Therapeutics
Other Prominent Vendors
• Athersys
• CHA Bio & Diostech
• Cytori Therapeutics
• Nuo Therapeutics
• Ocata Therapeutics
• Opexa Therapeutics
• Osiris Therapeutics
• Teva Pharmaceuticals
• United Therapeutics
Key Market Driver
• Effective Treatment of Life-threatening Diseases
• For a full, detailed list, view our report
Key Market Challenge
• Stringent Regulations
• For a full, detailed list, view our report
Key Market Trend
• Growing Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Process of Collection, Processing, and Storage of Cord Blood Cells
06.1 Donor Evaluation
06.2 Collection Methods
06.3 Processing and Storage Methods
06.4 Sample Retention and Length of Storage
07. Facts: Cord Blood Units
08. US FDA Approved Stem Cell UCB Product
08.1 Hemacord
08.1.1 Mechanism of Action
08.1.2 Side Effects
09. Pipeline Analysis
09.1 Information on Pipeline Candidates
09.1.1 PDA-002
09.1.2 PDA-001
09.1.3 PLX-PAD
09.1.4 PLX-R18
10. Market Landscape
10.1 Market Overview
10.2 Market Size and Forecast
10.3 Five Forces Analysis
11. Market Segmentation by Application
11.1 Cancers
11.2 Blood Disorders
11.3 Metabolic Disorders
11.4 Immune Disorders
11.5 Others
12. Market Segmentation by Storage
12.1 Public Cord Blood Bank
12.2 Private Cord Blood Bank
12.3 Public-Private Cord Blood Banks
13. Harmonization of Biobanking
14. Market Segmentation by End-user
14.1 Research Institutes
14.2 Pharmaceutical Companies
14.3 Biobanks
14.4 Hospitals
15. Geographical Segmentation
15.1 Stem Cell UCB Market in Americas
15.1.1 Market Size and Forecast
15.2 Stem Cell UCB Market in EMEA
15.2.1 Market Size and Forecast
15.3 Stem Cell UCB Market in APAC
15.3.1 Market Size and Forecast
16. Buying Criteria
17. Market Growth Drivers
18. Drivers and their Impact
19. Market Challenges
20. Impact of Drivers and Challenges
21. Market Trends
22. Trends and their Impact
23. Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2014
23.2.1 Caladrius Biosciences
23.2.2 Celgene Corp.
23.2.3 Mesoblast Ltd.
23.2.4 Pluristem Therapeutics
23.3 Other and Future Prominent Vendors
24. Global Stem Cell UCB Market: Key Takeaways
25. Key Vendor Analysis
25.1 Caladrious
25.1.1 Key Facts
25.1.2 Business Overview
25.1.3 Business Segmentation by Revenue 2014
25.1.4 Business Segmentation by Revenue 2013 and 2014
25.1.5 Geographical Segmentation by Revenue 2014
25.1.6 Business Strategy
25.1.7 Recent Developments
25.1.8 SWOT Analysis
25.2 Celgene
25.2.1 Key Facts
25.2.2 Business Overview
25.2.3 Business Strategy
25.2.4 Business Segmentation by Revenue
25.2.5 Sales by Geography
25.2.6 Key Information
25.2.7 SWOT Analysis
25.3 Mesoblast
25.3.1 Key Facts
25.3.2 Business Overview
25.3.3 Therapeutic Areas
25.3.4 Geographical Segmentation
25.3.5 Business Strategy
25.3.6 Recent Developments
25.3.7 SWOT Analysis
25.4 Pluristem
25.4.1 Key Facts
25.4.2 Business Overview
25.4.3 Geographical Presence
25.4.4 Business Strategy
25.4.5 Recent Developments
25.4.6 SWOT Analysis
26. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Donor Evaluation before Collection of Cord Blood Cells
Exhibit 3: Collection of Cord Blood Cells
Exhibit 4: Processing and Storage Methods of Cord Blood Cells
Exhibit 5: Stem Cell Transplantations by Patient Race in US
Exhibit 6: Pipeline Portfolio of Stem Cell UCB Products for Different Diseases
Exhibit 7: Global Stem Cell UCB Market 2014-2019 ($ millions)
Exhibit 8: Global Stem Cell UCB Market Segment by Application
Exhibit 9: Global Stem Cell UCB Market Segmentation by Storage
Exhibit 10: Organizations and Initiatives Toward Biobank Harmonization
Exhibit 11: Key Factors Involved in Harmonization of Biobanks
Exhibit 12: Key Focus Areas in Harmonization of Biobanks
Exhibit 13: Organizations and Initiatives in Harmonizing Science and Infrastructure
Exhibit 14: Initiatives on Biobanking Resource Tools and Databases
Exhibit 15: Global Stem Cell UCB Market Segment by End-user
Exhibit 16: Segmentation of Global Stem Cell UCB Market by Geography 2014
Exhibit 17: Stem Cell UCB Market in Americas 2014-2019 ($ millions)
Exhibit 18: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
Exhibit 19: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
Exhibit 20: Statistics of Stem Cell UCB Market by Geography
Exhibit 21: Global Stem Cell UCB Market: Key Takeaways
Exhibit 22: Caladrious: Business Segmentation by Revenue 2014
Exhibit 23: Caladrious: Business Segmentation by Revenue 2013 and 2014 ($ millions)
Exhibit 24: Caladrious: Geographical Segmentation by Revenue 2014
Exhibit 25: Celgene: Business Segmentation by Revenue 2011-2013 ($ millions)
Exhibit 26: Celgene: Sales by Geography 2013
Exhibit 27: Mesoblast: Therapeutic Areas
Exhibit 28: Mesoblast: Geographical Segmentation
Exhibit 29: PLuristem: Geographical Presence
